Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Roche Researcher Says A/H1N1 May Be Accidental Creation

This article was originally published in PharmAsia News

Executive Summary

An Australian researcher involved in development of Roche's Tamiflu (oseltamivir) is about to publish a report saying the A/H1N1 flu virus may have been created accidentally in the making of an antiviral. The World Health Organization is investigating the assertion of Adrian Gibbs, who collaborated on the Roche research. He said that in analyzing the genetic blueprint of the virus, he realized it may have evolved in the eggs he and others used to grow viruses used to make vaccines. The WHO was given an advance copy of the article ready for publication. In addition to indicating a need for greater security during research, a WHO officials said the discovery could allow them to get a better grasp on the ability of the virus to spread. (Click here for more

You may also be interested in...

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

New Zealand Reverse-Switches Codeine Judging Risks Outweigh Benefits

New Zealand is the latest country to reverse-switch all codeine-containing OTC drugs to prescription-only status following a protracted consultation process, during which industry's protestations fell on deaf ears.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts